Arcturus TherapeuticsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Arcturus is founded in San Diego around LUNAR lipid delivery and STARR self-amplifying mRNA. Not a seasonal US franchise company.
Arcturus lists on Nasdaq as ARCT (2017 reverse merger). The ticker predates any approved product.
CSL Seqirus collaboration and license for sa-mRNA COVID, flu, and other respiratory vaccines becomes effective 8 Dec 2022. Global rights sit with CSL, not a US launch by Arcturus.
Japan MHLW approves Kostaive (ARCT-154) on 28 Nov 2023, first licensed self-amplifying mRNA COVID vaccine. Meiji Seika distributes in Japan for CSL Seqirus.